A recent meta-analysis by Cai et al. [13] examined initial combination therapy in treatment-naïve type 2 diabetes patients, including combination therapy with an SGLT2 inhibitor and metformin. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.